Impact of Dyslipidemia on Clinical Outcomes Among Cancer Patients Treated With Immune Checkpoint Inhibitors.

Liang Y, Maeda O, Ishida S, Zennami K, Kimura T, Inoue S, Sano T, Sano Y, Naito Y, Miyata K, Shimizu D, Nishida K, Chrétien B, Kanda M, Akamatsu S, Ando Y

Open source

DOI
10.1002/cam4.72286
Published
2026 Sep
Container
Cancer medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cam4.72286,
  title = {Impact of Dyslipidemia on Clinical Outcomes Among Cancer Patients Treated With Immune Checkpoint Inhibitors.},
  author = {Liang Y and Maeda O and Ishida S and Zennami K and Kimura T and Inoue S and Sano T and Sano Y and Naito Y and Miyata K and Shimizu D and Nishida K and Chrétien B and Kanda M and Akamatsu S and Ando Y},
  year = {2026},
  journal = {Cancer medicine},
  doi = {10.1002/cam4.72286},
  url = {https://doi.org/10.1002/cam4.72286}
}

RIS

TY  - JOUR
TI  - Impact of Dyslipidemia on Clinical Outcomes Among Cancer Patients Treated With Immune Checkpoint Inhibitors.
AU  - Liang Y
AU  - Maeda O
AU  - Ishida S
AU  - Zennami K
AU  - Kimura T
AU  - Inoue S
AU  - Sano T
AU  - Sano Y
AU  - Naito Y
AU  - Miyata K
AU  - Shimizu D
AU  - Nishida K
AU  - Chrétien B
AU  - Kanda M
AU  - Akamatsu S
AU  - Ando Y
PY  - 2026
JO  - Cancer medicine
DO  - 10.1002/cam4.72286
UR  - https://doi.org/10.1002/cam4.72286
ER  - 

APA

Y, L., O, M., S, I., K, Z., T, K., S, I., T, S., Y, S., Y, N., K, M., D, S., K, N., B, C., M, K., S, A., & Y, A. (2026). Impact of Dyslipidemia on Clinical Outcomes Among Cancer Patients Treated With Immune Checkpoint Inhibitors.. Cancer medicine. https://doi.org/10.1002/cam4.72286

Source records